157 related articles for article (PubMed ID: 38252421)
1. KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes.
Assatova B; Willim R; Trevisani C; Haskett G; Kariya KM; Chopra K; Park SR; Tolstorukov MY; McCabe SM; Duffy J; Louissaint A; Huuhtanen J; Bhattacharya D; Mustjoki S; Koh MJ; Powers F; Morgan EA; Yang L; Pinckney B; Cotton MJ; Crabbe A; Ziemba JB; Brain I; Heavican-Foral TB; Iqbal J; Nemec R; Rider AB; Ford JG; Koh MJ; Scanlan N; Feith DJ; Loughran TP; Kim WS; Choi J; Roels J; Boehme L; Putteman T; Taghon T; Barnes JA; Johnson PC; Jacobsen ED; Greenberg SA; Weinstock DM; Jain S
Clin Cancer Res; 2024 Jun; 30(11):2514-2530. PubMed ID: 38252421
[TBL] [Abstract][Full Text] [Related]
2. KLRG1, Another Opportunity for a Breakthrough in MTCL.
Varma G; Diefenbach CS
Clin Cancer Res; 2024 Jun; 30(11):2300-2302. PubMed ID: 38568191
[TBL] [Abstract][Full Text] [Related]
3. E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells.
Yamauchi C; Fujii S; Kimura T; Kuwata T; Wada N; Mukai H; Matsumoto N; Fukayama M; Ochiai A
Int J Cancer; 2011 May; 128(9):2125-37. PubMed ID: 21387286
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of killer cell lectin-like receptor G1 expression on T cells.
Robbins SH; Terrizzi SC; Sydora BC; Mikayama T; Brossay L
J Immunol; 2003 Jun; 170(12):5876-85. PubMed ID: 12794113
[TBL] [Abstract][Full Text] [Related]
5. KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B.
Wijaya RS; Read SA; Schibeci S; Eslam M; Azardaryany MK; El-Khobar K; van der Poorten D; Lin R; Yuen L; Lam V; George J; Douglas MW; Ahlenstiel G
J Hepatol; 2019 Aug; 71(2):252-264. PubMed ID: 30905683
[TBL] [Abstract][Full Text] [Related]
6. Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas.
Jain S; Van Scoyk A; Morgan EA; Matthews A; Stevenson K; Newton G; Powers F; Autio A; Louissaint A; Pontini G; Aster JC; Luscinskas FW; Weinstock DM
Blood; 2019 Oct; 134(17):1430-1440. PubMed ID: 31383641
[TBL] [Abstract][Full Text] [Related]
7. Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1).
Voehringer D; Koschella M; Pircher H
Blood; 2002 Nov; 100(10):3698-702. PubMed ID: 12393723
[TBL] [Abstract][Full Text] [Related]
8. KLRG1 negatively regulates natural killer cell functions through the Akt pathway in individuals with chronic hepatitis C virus infection.
Wang JM; Cheng YQ; Shi L; Ying RS; Wu XY; Li GY; Moorman JP; Yao ZQ
J Virol; 2013 Nov; 87(21):11626-36. PubMed ID: 23966413
[TBL] [Abstract][Full Text] [Related]
9. CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells.
Wulf GG; Boehnke A; Chapuy B; Glass B; Hemmerlein B; Schroers R; Brenner MK; Truemper L
Haematologica; 2006 Jul; 91(7):886-94. PubMed ID: 16818275
[TBL] [Abstract][Full Text] [Related]
10. CMV drives the expansion of highly functional memory T cells expressing NK-cell receptors in renal transplant recipients.
Makwana N; Foley B; Fernandez S; Lee S; Irish A; Pircher H; Price P
Eur J Immunol; 2017 Aug; 47(8):1324-1334. PubMed ID: 28586095
[TBL] [Abstract][Full Text] [Related]
11. Expression of KLRG1 and CD127 defines distinct CD8
Wu H; Tang X; Kim HJ; Jalali S; Pritchett JC; Villasboas JC; Novak AJ; Yang ZZ; Ansell SM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34226281
[TBL] [Abstract][Full Text] [Related]
12. Development of Antihuman Killer Cell Lectin-Like Receptor Subfamily G Member 1 Monoclonal Antibodies for Flow Cytometry.
Asano T; Nanamiya R; Tanaka T; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):76-80. PubMed ID: 33900816
[TBL] [Abstract][Full Text] [Related]
13. Cutting edge: inhibitory functions of the killer cell lectin-like receptor G1 molecule during the activation of mouse NK cells.
Robbins SH; Nguyen KB; Takahashi N; Mikayama T; Biron CA; Brossay L
J Immunol; 2002 Mar; 168(6):2585-9. PubMed ID: 11884419
[TBL] [Abstract][Full Text] [Related]
14. Expression of inhibitory "killer cell lectin-like receptor G1" identifies unique subpopulations of effector and memory CD8 T cells.
Beyersdorf NB; Ding X; Karp K; Hanke T
Eur J Immunol; 2001 Dec; 31(12):3443-52. PubMed ID: 11745363
[TBL] [Abstract][Full Text] [Related]
15. Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype.
Göthert JR; Eisele L; Klein-Hitpass L; Weber S; Zesewitz ML; Sellmann L; Röth A; Pircher H; Dührsen U; Dürig J
Cancer Immunol Immunother; 2013 Nov; 62(11):1697-1709. PubMed ID: 24022692
[TBL] [Abstract][Full Text] [Related]
16. The NK receptor KLRG1 is dispensable for virus-induced NK and CD8+ T-cell differentiation and function in vivo.
Gründemann C; Schwartzkopff S; Koschella M; Schweier O; Peters C; Voehringer D; Pircher H
Eur J Immunol; 2010 May; 40(5):1303-14. PubMed ID: 20201037
[TBL] [Abstract][Full Text] [Related]
17. Combination blockade of KLRG1 and PD-1 promotes immune control of local and disseminated cancers.
Tata A; Dodard G; Fugère C; Leget C; Ors M; Rossi B; Vivier E; Brossay L
Oncoimmunology; 2021 Jun; 10(1):1933808. PubMed ID: 34188973
[TBL] [Abstract][Full Text] [Related]
18. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Hsi ED; Steinle R; Balasa B; Szmania S; Draksharapu A; Shum BP; Huseni M; Powers D; Nanisetti A; Zhang Y; Rice AG; van Abbema A; Wong M; Liu G; Zhan F; Dillon M; Chen S; Rhodes S; Fuh F; Tsurushita N; Kumar S; Vexler V; Shaughnessy JD; Barlogie B; van Rhee F; Hussein M; Afar DE; Williams MB
Clin Cancer Res; 2008 May; 14(9):2775-84. PubMed ID: 18451245
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis for E-cadherin recognition by killer cell lectin-like receptor G1 (KLRG1).
Nakamura S; Kuroki K; Ohki I; Sasaki K; Kajikawa M; Maruyama T; Ito M; Kameda Y; Ikura M; Yamamoto K; Matsumoto N; Maenaka K
J Biol Chem; 2009 Oct; 284(40):27327-35. PubMed ID: 19654330
[TBL] [Abstract][Full Text] [Related]
20. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
Rosario M; Liu B; Kong L; Collins LI; Schneider SE; Chen X; Han K; Jeng EK; Rhode PR; Leong JW; Schappe T; Jewell BA; Keppel CR; Shah K; Hess B; Romee R; Piwnica-Worms DR; Cashen AF; Bartlett NL; Wong HC; Fehniger TA
Clin Cancer Res; 2016 Feb; 22(3):596-608. PubMed ID: 26423796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
